Pfizer (NYSE:PFE) oncology updates and IBRANCE expansion unfold within S&P 500 healthcare segment, alongside lung cancer ...
Big pharma’s patent cliff may be overstated: layered IP, incremental innovation, and smart licensing extend exclusivity and ...
A vaccine that hits the tick rather than the germ carries one big advantage. Ticks deliver more than Lyme. The same bite can ...
DIA may be a flawed Dow ETF: opaque DJIA committee and price-weighted distortion underweight mega-cap tech. Read more macro ...
From July 1, Australia’s dominant supermarkets will have their prices monitored for “significantly excessive” pricing – ...
Shares of SpaceX (SPCX) have pulled back toward the $150 level after surging to a record high of $225.64 following the company's historic initial public offering on June 12. The decline comes as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results